ECM
VTVT icon

ExodusPoint Capital Management’s vTv Therapeutics VTVT Stock Holding History

ExodusPoint Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-553
Closed -$22K – 2719
2021
Q4 		$22K Buy
553
+205
+59% +$11K ﹤0.01% 2083
2021
Q3 		$21K Buy
+348
New +$26.2K ﹤0.01% 2015
2020
Q1 		– Sell
-402
Closed -$27K – 1682
2019
Q4 		$27K Buy
+402
New +$24.4K ﹤0.01% 1462

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ExodusPoint Capital Management's VTVT Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of vTv Therapeutics (VTVT) in Q1 2022, closing a stake of 553 shares — an estimated $22K sold.

ExodusPoint Capital Management first reported a position in VTVT in Q4 2019 and held it in 3 quarters. The position peaked at $27K in Q4 2019. 24 funds tracked by Wall St. Rank hold VTVT as of Q1 2022.

  • ExodusPoint Capital Management reported no remaining vTv Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 553 vTv Therapeutics shares in Q1 2022, an estimated $22K.
  • ExodusPoint Capital Management first reported a position in vTv Therapeutics in Q4 2019 and held it in 3 quarters.
  • ExodusPoint Capital Management's vTv Therapeutics position peaked at $27K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.